Anti-Human Abeta Recombinant Antibody (Gantenerumab) (CAT#: TAB-229)

Figure 6 Efficacy of mono- and combination treatments on brain amyloid burden and plaque number.

Animals were treated with BACE inhibitor RO5508887 at either 30 or 90 mg/kg daily (BI30, BI90), with anti-Aβ antibody gantenerumab (Gant) at 20 mg/kg weekly or with both compounds (BI30+Gant, BI90+Gant). A–D, Fluorescence images of entire sagittal brain sections after staining of amyloid plaques at study end. Representative images are shown after vehicle-treatment (A), treatment with BI90 (B), gantenerumab (C), and gantenerumab combined with BI90 (D). Notably, plaque reduction is most substantial in the animals that received both drugs. E, The quantification and statistical evaluation of the area surface occupied by plaques across all treatment groups for cortex and hippocampus. Decrease of plaque surface is significant while variable in treatment groups compared with vehicle-treated mice. The combination treatment significantly enhances the amyloid-plaque lowering for both the low- and the high-dose of RO5508887 in the cortex. F, Effect of mono- and combination treatments on total plaque number. Significantly enhanced efficacy by combination treatment is seen in both brain regions examined. Bars represent the mean of 10–4 animals (+SD).

Jacobsen, H., Ozmen, L., Caruso, A., Narquizian, R., Hilpert, H., Jacobsen, B.,... & Bohrmann, B. (2014). Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice. Journal of Neuroscience, 34(35), 11621-11630.

Figure 1 Anti-Human Abeta Antibody (TAB-229) in ELISA

ELISA analysis of TAB-229 was performed by coating with recombinant human Beta-amyloid 42 with His & GST Tag (10703-H20E2) (1 μg/mL). Then blocked with BSA and incubated with Anti-Human Abeta Antibody (TAB-229) at a starting concentration of 2.5 ng/mL. The HRP-conjugated goat anti-human IgG as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 2 Anti-Human Abeta Antibody (TAB-229) in WB

Western blot analysis was performed by loading 1 µg (lane 1, Non-Reduced) and 1 µg (lane 2, Reduced) recombinant human Beta-amyloid 42 with His & GST Tag (10703-H20E2) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least 1 hour. Membranes were probed with Anti-Human Abeta Antibody (TAB-229) at a concentration of 1 μg/mL overnight at 4°C on a rocking platform. Then probed with Goat anti-Human IgG HRP secondary antibody at a dilution of 1:8,000 for one hour. Chemiluminescent was detected.

Figure 3 Anti-Human Abeta Antibody in DB

Dot Blot analysis of TAB-229 was performed by coating with Human Abeta Protein (His Tag).